Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Diabetes
•
Endocrinology
•
Primary Care
What is your approach to addressing severe dawn phenomenon in your patients with diabetes?
Related Questions
Do you recommend up-titrating the Metformin dose of patients with T2DM who are at goal A1c in order to decrease their risk of diabetes-related delirium?
What patient specific factors outside of health insurance coverage do you use to decide which GLP1 R agonist or dual agonist therapy to start in patients with diabetes?
Do you recommend routinely monitoring pancreatic markers such as amylase and lipase while receiving GLP1 R agonist or dual agonist therapies to determine their risk of pancreatitis?
Is there a role for intermittent fasting as part of the management of a patient with long-standing type 2 diabetes and consistently poor glycemic control despite maximal therapy?
What is the preferred first-line non-insulin agent in patients with ketosis-prone diabetes during "remission" and evidence of preserved beta cell function?
Do you recommend adding low-dose Aspirin for primary prevention in patients with Type 2 Diabetes on Eliquis for another indication?
When do you recommend screening patients with T2DM for heart failure?
Is it safe to prescribe Invokana or Metformin for patients taking Biktarvy?
Do you recommend the use of GLP1 R agonist therapy in patients with T1DM for weight loss?
Is Metformin contraindicated in patients using long term oxygen therapy at home?
